Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. - Wikidata - wikimedia - TriplyDB

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.

http://www.wikidata.org/entity/Q44562612

about

Follicular lymphoma: 2012 update on diagnosis and management Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr Fluorescent imaging of cancerous tissues for targeted surgery.Follicular lymphoma: 2011 update on diagnosis and management Follicular lymphoma: 2014 update on diagnosis and management Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review.Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma.Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.Follicular lymphoma: still Six characters in search of an author?FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.PEGylation enables the specific tumor accumulation of a peptide identified by phage display.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Cancer radioimmunotherapy.(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma Activating Photodynamic Therapy in vitro with Cerenkov Radiation Generated from Yttrium-90.Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma.Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors.Treatment of follicular lymphoma: current status.Role of hematopoietic stem cell transplant in the management of follicular lymphoma.Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma.Radioactive antibodies: a historical review of selective targeting and treatment of cancer.Biology and treatment of follicular lymphoma.Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.Allogeneic stem cell transplantation in follicular lymphoma.Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.Antibody-mediated delivery of therapeutics for cancer therapy.Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts.Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma.Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.Follicular lymphoma: 2015 update on diagnosis and management.

P2860

Q22252956-046D7432-94C9-4AD1-B798-524D4062DD66 Q24633710-1B4104DD-291D-45A7-84C0-9E3C5AF8B31D Q26776480-E551413D-7020-4A0C-B6E7-27DCA842A909 Q26830905-14465CEF-7732-4F74-BD05-AB4A498C5595 Q26851450-B2F2D049-495C-4C2E-939E-1CE543B7C775 Q27021850-51D5BA6E-2706-4586-9CF6-CF6E5BB1CE24 Q33380518-E0496EB0-71BD-430E-AC51-6F6A7016B52F Q33392939-09765980-AED5-4026-8FCD-E83676378849 Q33402171-E1765F5A-3707-4FBD-BC32-356DDA6AA0EE Q33645793-5EBB3CCA-6780-4DFD-AA6E-0848A7FC2796 Q33927978-91C1BFA3-E23D-43A3-876B-DEDBF908498E Q34585773-F0E5B517-03E7-4C51-BCE7-17AA4AD95C73 Q34615563-72A445A1-C419-4EB5-91CA-0C17749B42BA Q34700655-C3D128FA-911D-4099-A913-FB2393326CBD Q35070045-405516DE-6AE8-43BE-BCB8-DBE405832074 Q35115650-2619C8FE-C32F-4446-B975-95792C9C6A03 Q35780034-781BECBA-8C03-43DF-8B75-BDA44DC526FF Q35786490-7007894F-8E04-4B8A-8383-A7CCF4BB61DC Q36092165-1FF0A344-A9FC-45D6-B987-44ACDD912414 Q36950052-971B76BC-6387-4AD7-ACFF-B7833C766639 Q36979699-626265CA-D45F-411F-9913-F19FC9FA3282 Q37169112-C58BAA74-4933-4B22-9867-AEBB013C56D1 Q37259751-C4BBB8BD-1855-4A22-997C-DFB2E8B6E782 Q37280915-BB258F54-DB65-488F-A283-F9AE078EC07B Q37533977-2AB97123-7B7A-43A3-9923-9AB64EA10F78 Q37731964-F3BFE9D1-8616-4062-AC21-45B697928F2B Q37796519-8F55AA3A-9E56-4FD7-970A-D8994C879101 Q37810118-04C1B846-23FB-46E1-9976-A17A8F64AD86 Q37877728-DA22C5B6-92AA-4AF6-92D7-84C19B239B6D Q37887151-A86848A1-BB18-4F87-93E5-BEB9DB186536 Q37930456-2679D18A-C170-4452-9725-A2501B228059 Q38174058-0CA807CB-7799-4BF0-8BD3-29E323D5372A Q38259725-AAC37659-0BCE-43F5-A744-94BEF5FBA665 Q38396244-4B69C9AE-333A-4962-A3EF-723DF2F0BA1E Q38473731-4A307D44-9B05-4434-9F67-6AA39F907227 Q38665425-5E224F03-5545-40B7-819C-A783CF3D3765 Q38696425-970E4B09-3746-4D94-9944-F2FF0FE2FFC1 Q39224455-E49ED0D2-9CD7-4719-9AB5-F92C2CEB83B2 Q39768589-DE52F047-9161-44D2-A856-4F1BC40FB255 Q40122693-874C6F89-72BB-4397-A2B2-BB63E7D92E6D

P2860

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.

http://www.wikidata.org/entity/Q44562612

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.

@en

Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.

@nl

type

label

Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.

@en

Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.

@nl

prefLabel

Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.

@en

Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.

@nl

P1433

Q44562612-ADB0366B-F69A-4C60-8820-466AB0D2D8D7

P1476

Q44562612-4B404B71-A90B-4D6B-BBDA-2BC89A54AE70

P2093

Q44562612-0E744E7F-1B89-4A44-90BB-E7D245276FAE

Q44562612-5FF8B2DF-5449-4DC2-8E99-A14C3D33C3BB

Q44562612-72F986C7-9B24-4E5D-A357-4B8EB8920CD1

Q44562612-738017FC-F125-47B4-8DA5-0C11475E8D3C

Q44562612-7FEC05BA-6AAF-477F-9010-F098AF56317D

Q44562612-B4B588DC-9C45-42C9-A6DC-6665A8F81C6B

Q44562612-BB7F90B6-6CC7-4B49-9C63-53EEC3258DE0

Q44562612-BE203D65-139E-4A7E-8C39-98BFEFE07AF0

Q44562612-CB253F34-FC7B-4934-8B8D-F586208A4F0E

P2860

Q44562612-7A8AC7FB-A881-434D-9FD7-1C4EF5D07DF3

P304

Q44562612-15CD9CC5-7F37-43E5-8274-867CD616431E

P31

Q44562612-5AE46624-1454-4EB0-8214-D53CC3824D47

P356

Q44562612-804D563E-7166-47EA-987C-5905A77B7BBD

P407

Q44562612-E58A42D4-1E2C-4D41-8055-577B899C886E

P433

Q44562612-F7555B95-5D5C-44B8-B15C-619CF1E8C5D0

P478

Q44562612-9F47BFB7-467F-4CFF-87A2-CE8CAE3AF599

P50

Q44562612-7CD6822E-1651-426F-AD2A-8065A48891E1

P577

Q44562612-D51C71D5-CA15-47C4-ABBF-E6F096D8CCFE

P5875

Q44562612-052E3873-2483-41BA-A9A8-0D3634493137

P698

Q44562612-B63FD468-B6BF-4F83-8938-BFD9E629DE74

P356

P1433

P1476

Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.

@en

P2093

Arturo Molina

http://www.w3.org/2001/XMLSchema#string

Christos Emmanouilides

http://www.w3.org/2001/XMLSchema#string

Gregory A Wiseman

http://www.w3.org/2001/XMLSchema#string

Ian W Flinn

http://www.w3.org/2001/XMLSchema#string

Katie Vo

http://www.w3.org/2001/XMLSchema#string

Mohamed Darif

http://www.w3.org/2001/XMLSchema#string

Roger Macklis

http://www.w3.org/2001/XMLSchema#string

Russell J Schilder

http://www.w3.org/2001/XMLSchema#string

Thomas E Witzig

http://www.w3.org/2001/XMLSchema#string

P2860

Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.

P304

1804-1810

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.22617

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6425910

http://www.w3.org/2001/XMLSchema#string

P698

17380530

http://www.w3.org/2001/XMLSchema#string